Year 2018 Vol. 26 No 4

GENERAL & SPECIAL SURGERY

E.YU. VASILYEVA, E.E. KASAKOVA, T.V. VAVILOVA

HEART-TYPE FATTY ACID-BINDING PROTEIN AS A PROGNOSTIC MARKER IN PATIENTS WITH ISCHEMIC HEART DISEASE AFTER PERCUTANEOUS CORONARY INTERVENTIONS

Almazov National Medical Research Centre, Saint-Petersburg,
The Russian Federation

Objective. To analyze the concentration of the heart-type fatty acid-binding protein (H-FABP) in patients with cardiovascular disease (CVD) before percutaneous coronary intervention (PCI) and within a year after coronary stenting.
Methods. This article presents the data collected through annual (one-year) observation of 71 patients after they had undergone PCI (58 patients, who didnt have any complications and 13 with restenosis or clinical significant stenosis of a new localization). All participants of the study had their H-FABP investigated before the operation as well as 3, 6 and 12 months after PCI.
Results. The H-FABP concentration values in the group of patients with CVD were significantly higher than in the control group (p <0.05). Three months after myocardial revascularization H-FABP concentration decreased significantly (p <0.05) in comparison with its initial value. Over one-year follow-up period H-FABP concentration showed the tendency to increase and by the end of the observation exceeded the baseline. In the group of patients with favorable course of postoperative period before the operation this marker level was significantly higher (p<0,05) than in patients with stenting complications. The correlation between the concentration of H-FABP and the accumulation of risk factors (R2=0,8, p<0,05) for cardiovascular diseases has been established. Presurgery period revealed a positive correlation between the concentration of H-FABP and the serum creatinine level (r = 0.36, p <0.05), as well as a negative correlation between H-FABP value and high-density lipoproteins (HDL) (r =-0.31, p<0.05), but none of these correlations were detected during other discreet observation moments.
Conclusions. There is a detected increase in H-FABP value in patients with chronic coronary heart disease, compared to healthy donors. The cumulation of cardiovascular risk factors leads to an increase in this marker level. There is no detected correlation between H-FABP concentration and clinical outcomes for patients after PCA throughout a year period.

Keywords: heart-type fatty acid-binding protein, percutaneous coronary intervention, coronary stenting, coronary artery disease, cardiac markers, cardiovascular disease
p. 431-439 of the original issue
References
  1. Dianov MA, Nikitina SIu, Ageeva LI, Aleksandrova GA, Zaichenko NM, Kirillova GN, Leonov SA, Mukhina TV, Ogryzko EV, Kharkova TL, Chumarina VZh, Shubochkina EM. Zdravookhranenie v Rossii. 2015: stat sb. Moscow, RF: Rosstat; 2015. 174 p. http://www.demoscope.ru/weekly/2016/0671/biblio01.php (in Russ.)
  2. Karpov IuA. Khronicheskaia ishemicheskaia bolezn serdtsa: novosti lecheniia. Consilium Medicum. 2016;18(1):38-44. https://medi.ru/info/3614/ (in Russ.)
  3. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296
  4. Undurti ND. Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease. Indian Heart J. 2016 Jan-Feb;68(1):16-18. Published online 2016 Jan 12. doi: 10.1016/j.ihj.2015.07.030
  5. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem. 1991 Apr;24(2):195-201. doi: 10.1016/0009-9120(91)90571-U
  6. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007 Apr 3;115(13):e356-75. doi: 10.1161/CIRCULATIONAHA.107.182882
  7. Sato Y, Kita T, Takatsu Y, Kimura T. Biochemical markers of myocyte injury in heart failure. Heart. 2004 Oct;90(10):1110-13. doi: 10.1136/hrt.2003.023895
  8. Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, Watanabe T, Nitobe J, Harada M, Suzuki S, Koyama Y, Kitahara T, Sasaki T, Kubota I. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail. 2007 Mar;13(2):120-27. doi: 10.1016/j.cardfail.2006.10.014
  9. Storch J, Thumser AE. Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem. 2010 Oct 22;285(43):32679-83. doi: 10.1074/jbc.R110.135210
  10. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med. 1997 Apr 17;336(16):1131-41. doi: 10.1056/NEJM199704173361603
  11. Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol. 2008 Mar;153 (Suppl ):S241-46. doi: 10.1038/sj.bjp.0707487
  12. Shurygina IA, Shurygin MG, Ayushinova NI, Kanya OV. Fibroblasts and their role in the development of connective tissue. Sib Med Zhurn (Irkutsk). 2012;110(3):8-12. http://smj.ismu.baikal.ru/index.php/osn/issue/view/43/2012-3 (in Russ.)
  13. Kim SJ, Depre C, Vatner SF. Novel mechanisms mediating stunned myocardium. Heart Fail Rev. 2003 Apr;8(2):143-53. https://link.springer.com/article/10.1023/A:1023040718319
  14. Muehlschlegel JD, Perry TE, Liu KY, Fox AA, Collard CD, Shernan SK, Body SC. Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery. Anesth Analg. 2010 Nov;111(5):1101-9. doi: 10.1213/ANE.0b013e3181dd9516
  15. Otaki Y, Watanabe T, Takahashi H, Hirayama A, Narumi T, Kadowaki S1, Honda Y, Arimoto T, Shishido T, Miyamoto T, Konta T, Shibata Y, Fukao A, Daimon M, Ueno Y, Kato T, Kayama T, Kubota I. Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. PLoS One. 2014 May 21;9(5):e94834. doi: 10.1371/journal.pone.0094834. eCollection 2014.
Address for correspondence:
197341, The Russian Federation,
Saint Petersburg, Akkuratova Str., 2,
Almazov National Medical Research Centre,
Central Clinical and Diagnostic Laboratory,
Tel.+7-921-325-90-12,
e-mail: elena-almazlab@yandex.ru,
Elena Yu. Vasilyeva
Information about the authors:
Vasilyeva Elena Yu., Post-Graduate Student of the Department of Laboratory Medicine and Genetic, Head of the Clinical and Diagnostic Laboratory, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation.
http://orcid.org/0000-0002-2115-8873
Kazakova Evgeniya E., Physician of the Clinical Laboratory Diagnostics, Central Clinical and Diagnostic Laboratory, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation.
http://orcid.org/0000-0002-0141-6986
Vavilova Tatiana V., MD, Professor, Head of the Department of Laboratory Medicine and Genetic, Almazov National Medical Research Centre, Saint Petersburg, Russian Federation.
http://orcid.org/0000-0001-8537-3639
Contacts | ©Vitebsk State Medical University, 2007-2023